Printer Friendly

CIRM extends retinal disease research grant.

NEW YORK, N.Y., April 09, 2015-The California Institute of Regenerative Medicine, the state's stem cell funding agency, has extended NeoStem, Inc.'s (NBS) study under a 2014 Early Translational grant from for research leading to the development of a treatment for retinal diseases, including macular degeneration and retinitis pigmentosa.

Under the $4 million grant made to the University of California, Irvine, NeoStem is entitled, through a sub-award, to $1 million of new funds adding to the original $500,000 awarded. The goals of the research are to generate three-dimensional retinal tissue, to investigate the ability of adult induced pluripotent stem cells to restore sight in rodent models of retinal degeneration and to make eventual preparations for clinical use of the tissue.

Contact: http://www.neostem.com

COPYRIGHT 2015 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:News Briefs
Publication:Stem Cell Lab World
Date:Apr 20, 2015
Words:127
Previous Article:Medidata technology platform broadened for better clinical trials.
Next Article:Company disparages investor class action lawsuit.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters